Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACAD NASDAQ:ARWR NASDAQ:ASND NASDAQ:JAZZ NASDAQ:ZLAB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACADACADIA Pharmaceuticals$22.02+1.3%$23.24$13.40▼$26.65$3.72B0.752.10 million shs1.38 million shsARWRArrowhead Pharmaceuticals$38.00+1.7%$30.59$9.57▼$40.29$5.25B1.131.88 million shs1.47 million shsASNDAscendis Pharma A/S$202.00+0.5%$199.92$118.03▼$216.45$12.46B0.41472,097 shs369,067 shsJAZZJazz Pharmaceuticals$138.53+0.3%$130.44$95.49▼$148.06$8.40B0.28688,893 shs511,450 shsZLABZai Lab$26.32-6.1%$31.97$23.82▼$44.34$2.94B1.08582,629 shs1.00 million shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACADACADIA Pharmaceuticals0.00%+5.41%+3.82%-5.29%+54.09%ARWRArrowhead Pharmaceuticals0.00%+3.23%+20.03%+141.42%+90.76%ASNDAscendis Pharma A/S0.00%-4.04%+6.46%+20.62%+58.20%JAZZJazz Pharmaceuticals0.00%+1.82%+8.40%+17.17%+24.66%ZLABZai Lab0.00%-6.96%-16.79%-29.19%-9.05%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACADACADIA Pharmaceuticals$22.02+1.3%$23.24$13.40▼$26.65$3.72B0.752.10 million shs1.38 million shsARWRArrowhead Pharmaceuticals$38.00+1.7%$30.59$9.57▼$40.29$5.25B1.131.88 million shs1.47 million shsASNDAscendis Pharma A/S$202.00+0.5%$199.92$118.03▼$216.45$12.46B0.41472,097 shs369,067 shsJAZZJazz Pharmaceuticals$138.53+0.3%$130.44$95.49▼$148.06$8.40B0.28688,893 shs511,450 shsZLABZai Lab$26.32-6.1%$31.97$23.82▼$44.34$2.94B1.08582,629 shs1.00 million shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACADACADIA Pharmaceuticals0.00%+5.41%+3.82%-5.29%+54.09%ARWRArrowhead Pharmaceuticals0.00%+3.23%+20.03%+141.42%+90.76%ASNDAscendis Pharma A/S0.00%-4.04%+6.46%+20.62%+58.20%JAZZJazz Pharmaceuticals0.00%+1.82%+8.40%+17.17%+24.66%ZLABZai Lab0.00%-6.96%-16.79%-29.19%-9.05%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACADACADIA Pharmaceuticals 2.65Moderate Buy$29.3333.21% UpsideARWRArrowhead Pharmaceuticals 2.78Moderate Buy$43.1413.53% UpsideASNDAscendis Pharma A/S 2.94Moderate Buy$249.8023.66% UpsideJAZZJazz Pharmaceuticals 2.76Moderate Buy$180.0029.94% UpsideZLABZai Lab 2.63Moderate Buy$56.35114.10% UpsideCurrent Analyst Ratings BreakdownLatest ZLAB, ASND, ARWR, ACAD, and JAZZ Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/25/2025JAZZJazz PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)10/24/2025JAZZJazz PharmaceuticalsMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$183.0010/24/2025ARWRArrowhead PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/24/2025ASNDAscendis Pharma A/SWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/24/2025ZLABZai LabWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/22/2025JAZZJazz PharmaceuticalsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$170.0010/21/2025ACADACADIA PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform ➝ Buy$33.0010/20/2025JAZZJazz PharmaceuticalsMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$167.00 ➝ $180.0010/17/2025ASNDAscendis Pharma A/SRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageStrong-Buy$271.0010/16/2025ASNDAscendis Pharma A/SRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy10/14/2025ACADACADIA PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)(Data available from 10/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACADACADIA Pharmaceuticals$957.80M3.88$0.70 per share31.24$4.40 per share5.00ARWRArrowhead Pharmaceuticals$3.55M1,479.97N/AN/A$1.54 per share24.68ASNDAscendis Pharma A/S$393.54M31.66N/AN/A($1.88) per share-107.45JAZZJazz Pharmaceuticals$4.07B2.07$30.38 per share4.56$67.72 per share2.05ZLABZai Lab$398.99M7.37N/AN/A$7.68 per share3.43Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACADACADIA Pharmaceuticals$226.45M$1.3316.5628.977.6121.80%14.69%9.41%11/5/2025 (Estimated)ARWRArrowhead Pharmaceuticals-$599.49M-$1.28N/AN/AN/AN/A-40.91%-11.62%11/25/2025 (Estimated)ASNDAscendis Pharma A/S-$409.12M-$5.16N/A841.67N/A-54.94%N/A-24.31%11/13/2025 (Estimated)JAZZJazz Pharmaceuticals$560.12M-$6.73N/A7.408.23-9.91%5.02%1.73%11/5/2025 (Estimated)ZLABZai Lab-$257.10M-$2.04N/AN/AN/A-49.68%-27.32%-18.85%11/6/2025 (Confirmed)Latest ZLAB, ASND, ARWR, ACAD, and JAZZ EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/13/2025Q3 2025ASNDAscendis Pharma A/S-$0.49N/AN/AN/AN/AN/A11/6/2025Q3 2025ZLABZai Lab-$0.22N/AN/AN/A$150.24 millionN/A11/5/2025Q3 2025ACADACADIA Pharmaceuticals$0.14N/AN/AN/A$276.52 millionN/A11/5/2025Q3 2025JAZZJazz Pharmaceuticals$5.87N/AN/AN/A$1.11 billionN/A8/7/2025Q3 2025ARWRArrowhead Pharmaceuticals-$0.94-$1.26-$0.32-$1.26$29.01 million$27.77 million8/7/2025Q2 2025ASNDAscendis Pharma A/S-$1.42-$0.93+$0.49-$0.93$163.17 million$216.28 million8/7/2025Q2 2025ZLABZai Lab-$0.37-$0.37N/A-$0.37$125.66 million$109.98 million8/6/2025Q2 2025ACADACADIA Pharmaceuticals$0.14$0.16+$0.02$0.16$263.07 million$264.57 million8/5/2025Q2 2025JAZZJazz Pharmaceuticals-$5.61-$8.25-$2.64-$11.74$1.05 billion$1.05 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACADACADIA PharmaceuticalsN/AN/AN/AN/AN/AARWRArrowhead PharmaceuticalsN/AN/AN/AN/AN/AASNDAscendis Pharma A/SN/AN/AN/AN/AN/AJAZZJazz PharmaceuticalsN/AN/AN/AN/AN/AZLABZai LabN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACADACADIA PharmaceuticalsN/A2.912.83ARWRArrowhead Pharmaceuticals0.394.874.87ASNDAscendis Pharma A/SN/A1.020.69JAZZJazz Pharmaceuticals1.171.621.37ZLABZai LabN/A3.122.93Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACADACADIA Pharmaceuticals96.71%ARWRArrowhead Pharmaceuticals62.61%ASNDAscendis Pharma A/SN/AJAZZJazz Pharmaceuticals89.14%ZLABZai Lab41.65%Insider OwnershipCompanyInsider OwnershipACADACADIA Pharmaceuticals26.50%ARWRArrowhead Pharmaceuticals4.30%ASNDAscendis Pharma A/S40.00%JAZZJazz Pharmaceuticals4.30%ZLABZai Lab4.96%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACADACADIA Pharmaceuticals510168.71 million124.00 millionOptionableARWRArrowhead Pharmaceuticals400138.26 million132.31 millionOptionableASNDAscendis Pharma A/S1,01761.69 million37.02 millionOptionableJAZZJazz Pharmaceuticals2,80060.66 million58.05 millionOptionableZLABZai Lab1,869111.76 million106.22 millionOptionableZLAB, ASND, ARWR, ACAD, and JAZZ HeadlinesRecent News About These CompaniesZai Lab (NASDAQ:ZLAB) Receives "Sell (D-)" Rating from Weiss RatingsOctober 25 at 4:05 PM | marketbeat.comZai Lab (NASDAQ:ZLAB) Stock Price Down 4.6% - Time to Sell?October 25 at 3:21 PM | marketbeat.comZai Lab Announces Updated Phase 1 Data for Zocilurtatug Pelitecan (formerly ZL-1310), Demonstrating Potential as a First-in-Class/Best-in-Class DLL3-Targeted ADC for Small Cell ...October 25 at 8:35 AM | theglobeandmail.comLeerink Partnrs Has Bearish Estimate for Zai Lab Q3 EarningsOctober 25 at 2:41 AM | americanbankingnews.comZai Lab Limited (ZLAB) Discusses Updated Monotherapy Phase I Data for Suzhou and Outlines Next Steps in Clinical Development TranscriptOctober 24 at 3:02 PM | seekingalpha.comZai Lab Limited (ZLAB) Discusses Updated Monotherapy Phase I Data for Suzhou and Outlines Next Steps in Clinical Development - SlideshowOctober 24 at 12:48 PM | seekingalpha.comQ3 Earnings Estimate for Zai Lab Issued By Leerink PartnrsOctober 23 at 6:29 AM | marketbeat.comZai Lab Secures RMB300 Million Debt FacilityOctober 16, 2025 | msn.comA Look at Zai Lab (NasdaqGM:ZLAB) Valuation Following Key Clinical Progress and New Data AnnouncementOctober 16, 2025 | finance.yahoo.comCould Zai Lab’s (ZLAB) Pipeline Milestone Reveal Shifting Dynamics in Its Oncology Growth Narrative?October 16, 2025 | finance.yahoo.comZai Lab to Announce Third Quarter 2025 Financial Results and Recent Corporate Updates on November 6, 2025October 15, 2025 | businesswire.comZai Lab falls -6.9%October 14, 2025 | msn.comZai Lab (NASDAQ:ZLAB) Trading Down 6.2% - Here's What HappenedOctober 14, 2025 | marketbeat.comZai Lab Announces Oral Presentation of Updated Data from Global Phase 1 Trial of Zocilurtatug Pelitecan (ZL-1310), a Potential First-in-Class DLL3-Targeted ADC, at 2025 AACR-NCI-EORTC ConferenceOctober 13, 2025 | businesswire.comStocks Showing Improved Relative Strength: Zai Lab ADROctober 9, 2025 | msn.comWeiss Ratings Reaffirms Sell (D-) Rating for Zai Lab (NASDAQ:ZLAB)October 8, 2025 | marketbeat.comZai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Given Consensus Rating of "Moderate Buy" by BrokeragesOctober 8, 2025 | marketbeat.comZai Lab (NASDAQ:ZLAB) Shares Gap Up - Still a Buy?September 30, 2025 | marketbeat.comZai Lab (ZLAB) Gets a Buy from Cantor FitzgeraldSeptember 21, 2025 | theglobeandmail.comZai Lab Limited (ZLAB): A Bull Case TheorySeptember 16, 2025 | finance.yahoo.comZai Lab (NASDAQ:ZLAB) Insider Acquires $289,100.00 in StockSeptember 13, 2025 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeZLAB, ASND, ARWR, ACAD, and JAZZ Company DescriptionsACADIA Pharmaceuticals NASDAQ:ACAD$22.02 +0.29 (+1.33%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$21.99 -0.03 (-0.14%) As of 10/24/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.Arrowhead Pharmaceuticals NASDAQ:ARWR$38.00 +0.65 (+1.74%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$38.35 +0.35 (+0.92%) As of 10/24/2025 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.Ascendis Pharma A/S NASDAQ:ASND$202.00 +0.99 (+0.49%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$202.50 +0.50 (+0.25%) As of 10/24/2025 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.Jazz Pharmaceuticals NASDAQ:JAZZ$138.53 +0.35 (+0.25%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$138.42 -0.12 (-0.08%) As of 10/24/2025 06:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.Zai Lab NASDAQ:ZLAB$26.32 -1.70 (-6.07%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$26.56 +0.24 (+0.91%) As of 10/24/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 10/20 - 10/24 Freeport-McMoRan Posts Strong Earnings Despite Indonesia Shutdown Tractor Supply Stock Looks Like a Buy-and-Hold Winner Tesla’s Earnings Review: Does the Juice Justify the Squeeze? Warner Bros. Bidding War Potential: How High Could WBD Shares Go? Fal.Con Europe Could Be CrowdStrike’s Early Earnings Catalyst Logitech Eyes Breakout Before Earnings—Citigroup Sees 30% Upside Boeing Takes Off as FAA Greenlights 737 MAX Production Boost Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
